News &amp; Updates

BXOS110, a novel PSD-95* protein inhibitor, has shown potential for improving functional outcomes in patients with acute ischaemic stroke, according to the BEST** trial presented at ISC 2025.

Novel BXOS110 promising neuroprotective agent in acute ischaemic stroke

CU Medicine’s roadmap of translational innovation and entrepreneurship

The Faculty of Medicine of Chinese University of Hong Kong (CU Medicine) will focus on strengthening translational medicine and entrepreneurship, nurturing a new generation of clinician-scientists, and promoting research in the Guangdong-Hong Kong-Macao Greater Bay Area as part of its 2025 development plan, according to its leadership team led by Dean of Medicine, Professor Philip Chiu.

CU Medicine’s roadmap of translational innovation and entrepreneurship

Lung function a potential biomarker for glaucoma

Lung function measures are associated with risk of glaucoma, indicating their potential role as biomarkers for the optic neuropathy with a devastating visual impact, researchers from the Chinese University of Hong Kong, Princes of Wales Hospital and Hong Kong Eye Hospital have reported.

Lung function a potential biomarker for glaucoma

Pre-symptomatic diagnosis and treatment: A game changer for SMA

Spinal muscular atrophy (SMA) is a progressive neurodegenerative disease that typically begins to manifest in infancy or childhood. Early diagnosis and prompt treatment before symptom onset can significantly improve clinical outcomes, including survival and attainment of motor milestones. At an industry-sponsored symposium co-organized by the Hong Kong Society of Neuromuscular Diseases (HKSNMD), Dr Astrid Blaschek of Dr von Hauner Children's Hospital in Munich, Germany, discussed implementation of the genetic newborn screening (NBS) programme for SMA in Germany and her clinical experience in managing children with SMA with available disease-modifying therapies, including risdiplam.

Pre-symptomatic diagnosis and treatment: A game changer for SMA

Do GLP-1 RAs reduce VTE risk in T2D?

New data from a study of 656,588 patients with type 2 diabetes (T2D) demonstrate a lower risk of venous thromboembolism (VTE), regardless of obesity status, when treated with glucagon-like peptide 1 (GLP-1) receptor agonists (GLP-1 RAs).

Do GLP-1 RAs reduce VTE risk in T2D?

Semaglutide linked to modest increase in risk of nonarteritic anterior ischemic optic neuropathy

The use of semaglutide among individuals with type 2 diabetes (T2D) appears to carry a modest increase in the risk nonarteritic anterior ischemic optic neuropathy (NAION), according to a retrospective study.

Semaglutide linked to modest increase in risk of nonarteritic anterior ischemic optic neuropathy

Severe maternal morbidity up by fourfold in presence of CRC

27 Feb 2025 by

Pregnant women with colorectal cancer (CRC) face a considerably increased likelihood of severe maternal morbidity, including disseminated intravascular coagulation, acute respiratory distress syndrome, and hysterectomy, among others, according to a study.

Severe maternal morbidity up by fourfold in presence of CRC

27 Feb 2025

TNFi eases TMJ inflammation in patients with JIA

Treatment with tumour necrosis factor inhibitor (TNFi) can reduce the orofacial signs, symptoms, and MRI-derived inflammation score in patients with juvenile idiopathic arthritis (JIA)-related temporomandibular joint (TMJ) arthritis, a study has shown.

TNFi eases TMJ inflammation in patients with JIA

Mevrometostat plus enzalutamide improves outcomes in mCRPC patients

27 Feb 2025 by

Treatment with mevrometostat (MEV), an enhancer of zeste homolog 2 inhibitor, in combination with enzalutamide (ENZ) results in better survival outcomes and response than ENZ alone among patients with metastatic castration-resistant prostate cancer (mCRPC), reports a study presented at ASCO GU 2025. The combined therapy also demonstrates a favourable safety profile.

Mevrometostat plus enzalutamide improves outcomes in mCRPC patients

27 Feb 2025

Obesity impacts symptom severity, prednisone dosing in PMR

Obesity appears to have an impact on both symptom severity and the use of prednisone in patients with polymyalgia rheumatica (PMR), suggests a study. This is potentially driven by subjective pain perception rather than increased inflammation.

Obesity impacts symptom severity, prednisone dosing in PMR